Expression and Role of E-Cadherin, β-Catenin, and Vimentin in Human Papillomavirus–Positive and Human Papillomavirus–Negative Oropharyngeal Squamous Cell Carcinoma

Hesham Mohamed, Caj Haglund, Lauri Jouhi, Timo Atula, Jaana Hagström*, and Antti Mäkitie*

Department of Pathology (HM, JH), Department of Surgery (CH), and Department of Otorhinolaryngology—Head and Neck Surgery (LJ, TA, AM), University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Histology, Omar Al-Mukhtar University, Al-Bayda, Libya (HM); Research Program Unit, Translational Cancer Biology (CH, JH) and Research Program in Systems Oncology, Faculty of Medicine (AM), University of Helsinki, Helsinki, Finland; Department of Oral Pathology and Radiology (JH), University of Turku, Turku, Finland; and Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (AM)

Summary

Oropharyngeal squamous cell carcinoma (OPSCC) is subclassified by the World Health Organization into two different entities: human papillomavirus (HPV)-positive and HPV-negative tumors. HPV infection promotes the epithelial-to-mesenchymal transition (EMT) and transformation of keratinocyte stem cells into cancer stem cells. EMT is a crucial process in the carcinogenesis of epithelial-derived malignancies, and we aimed to study the role of its markers in OPSCC. This study consists of 202 consecutive OPSCC patients diagnosed and treated with curative intent. We examined E-cadherin, β-catenin, and vimentin expression using immunohistochemistry and compared these with tumor and patient characteristics and treatment outcome. We found that the cell-membranous expression of β-catenin was stronger in HPV-positive than in HPV-negative tumors, and it was stronger in the presence of regional metastasis. The stromal vimentin expression was stronger among HPV-positive tumors. A high E-cadherin expression was associated with tumor grade. No relationship between these markers and survival emerged. In conclusion, β-catenin and vimentin seem to play different roles in OPSCC: the former in the tumor tissue itself, and the latter in the tumor stroma. HPV infection may exploit the β-catenin and vimentin pathways in carcinogenic process. More, β-catenin may serve as a marker for the occurrence of regional metastasis: (J Histochem Cytochem XX: XXX–XXX, XXXX)

Keywords
cancer, immunohistochemistry, p16, tissue microarray

Introduction

Epithelial-to-mesenchymal transition (EMT) plays an important role in the carcinogenesis of epithelial-derived tumors. During this process, the epithelial cells lose their cell polarity and cell-to-cell adhesion, and acquire invasive and migratory properties. These cells express cancer stem cell markers and are, therefore,
named cancer stem cells (CSCs).\(^1,2\) CSC markers are expressed in various cancers, including oral and oropharyngeal cancers, and their expression may be valuable in predicting clinical outcome.\(^3,4\) Recently, human papillomavirus (HPV) was shown to promote the transformation of keratinocyte stem cells to become CSCs, possibly explaining the high metastasis rate of HPV-related oropharyngeal tumors.\(^5\) The p16 gene is a well-known tumor suppressor protein, encoded by a gene localized on chromosome 9p21.\(^6\) Protein p16 expression highly correlates with the presence of HPV16 in oropharyngeal squamous cell carcinoma (OPSCC),\(^7,8\) and patients with HPV-positive OPSCC exhibit better survival compared with their virus-negative counterparts.\(^8,9\)

The cadherin family is a group of glycoproteins regulating the Ca\(^{2+}\)-dependent cell-to-cell adhesion mechanism. Takeichi\(^10\) has identified E-cadherin as the first member of the cadherin family. It is a tumor suppressor,\(^11\) and its low expression is a hallmark for EMT.\(^12\) In addition, a low E-cadherin expression is a characteristic of many types of cancers\(^3,13,14\) and typically a marker of poor prognosis.\(^15,16\) Catenins (\(\alpha\), \(\beta\), and \(\gamma\)) are cytoplasmic proteins, first described by Ozawa et al.\(^17\) These proteins connect E-cadherin to actin filaments in adherent junctions\(^18\) and are involved in signal transduction via cell adhesion,\(^17\) particularly \(\beta\)-catenin,\(^19\) which is tightly associated with E-cadherin.\(^18\) In addition to the aforementioned functions of the \(\beta\)-catenin protein, the \(\beta\)-catenin gene is also known as an oncogene located on chromosome 3p21, a region involved in cancer development.\(^20\) Furthermore, the \(\beta\)-catenin protein may be involved in cancer pathogenesis through the Wnt/\(\beta\)-catenin pathway.\(^21–23\) Vimentin is a protein normally expressed in mesenchymal cells.\(^24,25\) In normal epithelial tissues, vimentin is involved in cell adhesion through its interaction with vinculin and integrin.\(^26,27\) Again, it may play a role in the adhesion and transcellular migration of lymphocytes through the endothelial cells.\(^28\) In addition, vimentin may affect DNA transcription and cell apoptosis by interacting with the transcriptional determinant of p53.\(^29\) Moreover, vimentin is a canonical marker of EMT, and its positivity serves as a valuable marker for metastasis occurrence in epithelial-derived malignancies.\(^30,31\)

Here, we studied the expression of vimentin, E-cadherin, and \(\beta\)-catenin in OPSCC. We compared their expression levels with clinical parameters and outcomes, and examined the relationship between these markers and HPV status.

Figure 1 describes the workflow in which the main procedures, results, and conclusions are described in this publication.

---

**Materials and Methods**

**Patient Selection**

Altogether, 331 patients with oropharyngeal cancer were diagnosed and treated at the Department of
Otorhinolaryngology—Head and Neck Surgery, Helsinki University Hospital (Helsinki, Finland), between January 1, 2000, and December 31, 2009. Of these patients, the following were excluded from the study: those receiving palliative treatment \((n=44)\), those with concurrent \((n=5)\) or previously treated head and neck squamous cell carcinoma (HNSCC) \((n=11)\), a histology other than squamous cell carcinoma (SCC) or an SCC subtype \((n=18)\), or those for whom tumor tissue was unavailable \((n=51)\) for E-cadherin and \(\beta\)-catenin, and \(n=52\) for vimentin). Thus, our study cohort comprised 202 patients for E-cadherin and \(\beta\)-catenin and 201 for vimentin expression analysis.

**Hospital Records Data Source**

We recorded clinicopathological data from patient files. The median follow-up time for patients was 5 years, but all patients had a minimum follow-up of 3 years or until death. We obtained the dates and causes of death from Statistics Finland. The patient data are described in detail in our previous publication. The Research Ethics Board of the Hospital District of Helsinki and Uusimaa approved the study design, and an institutional study permission was granted.

**Immunohistochemistry**

We obtained formalin-fixed and paraffin-embedded surgical tissue samples from the archives of the Department of Pathology. The slides were re-evaluated by an experienced head and neck pathologist (J.H.), and cancer areas were marked on the slides. We prepared tissue microarray (TMA) blocks from the donor paraffin blocks. From the selected cancer areas, four tumor spots were detached for each case by a 1-mm needle and placed into a recipient paraffin block with a semiautomatic tissue microarrayer (Beecher Instruments; Silver Spring, MD). From the TMA blocks, 4-μm-thick sections were cut, deparaffinized in xylene, and rehydrated through a graded alcohol series. We accomplished antigen retrieval by heating the samples in 98C EDTA buffer (pH 9.0) for 24 min in a pretreatment PT Module (Lab Vision Corp.; Fremont, CA). The samples were then cooled to room temperature for 1 hr. Endogenous peroxidase was inactivated by incubating the specimens in Dako REAL Peroxidase-Blocking Solution for 5 min. We used a specific primary antibody for each marker: mouse anti-human p16\(^{INK4a}\) monoclonal antibody (MAB) incubated for 30 min (9517 CINtec Histology Kit; mtm laboratories, Heidelberg, Germany), mouse anti-\(\beta\)-catenin MAB diluted to 1:400 and incubated for 30 min (CAT-5H10, 18-0226; Invitrogen Corporation, Carlsbad, CA; www.invitrogen.com), mouse anti-E-cadherin MAb diluted to 1:200 and incubated for 30 min (HECD-1, 13-1700; Invitrogen Corporation), and mouse anti-vimentin MAB diluted to 1:4000 and incubated for 1 hr (V9, M0725; Dako; Santa Clara, CA; https://www.citeab.com/antibodies/2414896-m0725-vimentin-concentrate). Staining was achieved using the Dako Real EnVision Detection System and peroxidase DAB+ with an Autostainer (LabVision; Fremont, CA).

For all markers, we used colon cancer tissue as the positive control, except for p16, for which the positive control was tongue squamous cell carcinoma tissue. In each staining, the negative control was a slide without the primary antibody.

**HPV In Situ Hybridization and p16 Immunostaining**

HPV in situ hybridization (ISH) and p16 immunohistochemical staining were performed previously by our group. We have achieved the Ventana Inform HPV ISH assay using a high-risk HPV probe (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66) and the iVIEW Blue detection kit in Benchmark XT series stainer (Ventana Medical Systems; Tuscon, AZ). In this study, only HPV+ p16+ tumors were considered HPV-related OPSCC.

**Scoring**

Two independent investigators (H.M. and J.H.) evaluated the immunopositivity in tumor cells in a blinded manner without knowledge of the clinicopathological data. In the case of any disparity, an accordant score was used for further analysis. We scored both the cytoplasmic and cell-membranous expression of \(\beta\)-catenin, and the cell-membranous expression of E-cadherin and the cytoplasmic expression of vimentin according to the intensity. For \(\beta\)-catenin and E-cadherin, the scoring was as follows: negative (0), weakly positive (1), moderately positive (2), or strongly positive (3). Vimentin was scored as negative (0), weak (1), and strong (2). For all markers, the highest score for the four spots from each tumor was used for further analysis in a blinded manner.

**Statistical Analysis**

We used SPSS version 20.0 (SPSS, Inc.; Chicago, IL) to analyze all data. The scoring results for different markers were compared with clinical and pathological data. We used the Chi-square test to analyze the material with asymptotic and exact \(p\) values when most suitable, except when examining the relationships between the markers and patients’ age, which were analyzed using ANOVA. The Kaplan–Meier estimate was used to calculate the 5-year disease-specific
survival (DSS) rate and recurrence-free survival (RFS) rate, using the log-rank statistical test. We considered value of $p<0.05$ as statistically significant.

**Results**

**Expression of Markers**

The cell-membranous expression of E-cadherin and both the cytoplasmic and cell-membranous expression of β-catenin were present in the tumor cells, whereas vimentin was expressed in the tumor-related stromal tissue cells. In the tumor cells, we found no vimentin positivity (Figs. 2 and 3).

**Relationship Between E-Cadherin, β-Catenin, and Vimentin Expression**

E-cadherin was positively associated with both the cell-membranous and cytoplasmic expression of β-catenin (Table 1). In addition, vimentin expression was
associated with cell-membranous β-catenin, although we found no significant relationship between the vimentin and E-cadherin expression (Table 2).

**Relationship Between the Markers and HPV Status**

**E-Cadherin.** E-cadherin expression was almost identical in both HPV-positive and HPV-negative tumors (96% and 94%, respectively). E-cadherin expression did not correlate with HPV status ($p=0.796$) (Table 1).

**β-Catenin.** The cell-membranous expression of β-catenin appeared in 97% (98/101) of HPV-positive tumors and in 91% (92/101) of HPV-negative tumors. The cell-membranous expression of β-catenin was stronger in HPV-positive than in HPV-negative tumors ($p=0.001$) (Table 3).

Cytoplasmic β-catenin expression was identified in 81% of HPV-positive and in 77% of HPV-negative tumors. We found no correlation between the cytoplasmic expression of β-catenin and HPV status ($p=0.952$) (Table 3).

**Vimentin.** Vimentin expression was negative in OPSCC cells in all tumor samples. We observed vimentin immunoexpression in tumor-associated stromal tissue in 99% of HPV-positive and 100% of HPV-negative tumors.
Table 1. Expression of E-Cadherin and Its Association With Clinicopathological Factors in OPSCC.

| Variables                  | E-Cadherin Scoring |       |       |       |       |       |
|----------------------------|--------------------|-------|-------|-------|-------|-------|
|                            | Negative           | Weak  | Moderate | Strong | Total Number | p Value |
| Sex                        |                    |       |         |        |              |        |
| Men                        | 8                  | 23    | 73      | 46     | 150          | 0.414* |
| Women                      | 2                  | 7     | 24      | 19     | 52           |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          |        |
| Smoking                    |                    |       |         |        |              |        |
| Never                      | 1                  | 3     | 14      | 8      | 26           |        |
| Ex-smoker                  | 2                  | 12    | 22      | 13     | 49           |        |
| Regularly                  | 5                  | 12    | 48      | 31     | 96           |        |
| Total                      | 8                  | 27    | 84      | 52     | 171          | 0.798**|
| Heavy drinking             |                    |       |         |        |              |        |
| No                         | 1                  | 13    | 28      | 19     | 61           |        |
| Previously                 | 1                  | 3     | 15      | 5      | 24           |        |
| Yes                        | 1                  | 4     | 19      | 14     | 38           |        |
| Total                      | 3                  | 20    | 62      | 38     | 123          | 0.414**|
| HPV                        |                    |       |         |        |              |        |
| Positive                   | 4                  | 16    | 48      | 33     | 101          |        |
| Negative                   | 6                  | 14    | 49      | 32     | 101          |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | 0.796* |
| Grade                      |                    |       |         |        |              |        |
| Gr1                        | 0                  | 1     | 8       | 9      | 18           |        |
| Gr2                        | 2                  | 7     | 48      | 21     | 78           |        |
| Gr3                        | 8                  | 22    | 41      | 35     | 106          |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | 0.020* |
| T class                    |                    |       |         |        |              |        |
| T1                         | 3                  | 5     | 19      | 11     | 38           |        |
| T2                         | 2                  | 11    | 40      | 23     | 76           |        |
| T3                         | 1                  | 7     | 21      | 17     | 46           |        |
| T4                         | 4                  | 7     | 17      | 14     | 42           |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | 0.944* |
| N class                    |                    |       |         |        |              |        |
| N0                         | 1                  | 4     | 21      | 13     | 39           |        |
| N+                         | 9                  | 26    | 76      | 52     | 163          |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | 0.370* |
| Stage                      |                    |       |         |        |              |        |
| I–II                       | 0                  | 1     | 19      | 10     | 30           |        |
| III–IV                     | 10                 | 29    | 78      | 55     | 172          |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | 0.101* |
| Tumor site                 |                    |       |         |        |              |        |
| Anterior wall              | 3                  | 9     | 25      | 24     | 61           |        |
| Lateral wall               | 6                  | 19    | 56      | 36     | 117          |        |
| Posterior wall             | 0                  | 0     | 1       | 2      | 3            |        |
| Superior wall              | 1                  | 2     | 15      | 3      | 21           |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | 0.449**|
| Cell-membranous β-catenin expression |                |       |         |        |              |        |
| Negative                   | 2                  | 4     | 5       | 1      | 12           |        |
| Weak                       | 3                  | 5     | 15      | 8      | 31           |        |
| Moderate                   | 4                  | 10    | 41      | 15     | 70           |        |
| Strong                     | 1                  | 11    | 36      | 41     | 89           |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | <0.001***|
| Cytoplasmic β-catenin expression |                |       |         |        |              |        |
| Negative                   | 7                  | 10    | 17      | 9      | 43           |        |
| Weak                       | 2                  | 2     | 12      | 4      | 20           |        |
| Moderate                   | 1                  | 8     | 31      | 16     | 56           |        |
| Strong                     | 0                  | 10    | 37      | 36     | 83           |        |
| Total                      | 10                 | 30    | 97      | 65     | 202          | <0.001***|

Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma. Boldfaced values are statistically significant for those $P < 0.05$ and statistically highly significant for those $P < 0.001$.

*a*Chi-square test with asymptotic $p$-value. **Chi-square test with exact $p$-value.
Table 2. Expression of Vimentin and its Association With Clinicopathological Factors in OPSCC.

| Variables         | Vimentin Scoring | Total | p Value |
|-------------------|------------------|-------|---------|
|                   | Negative | Weak | Strong | Number |       |
| Sex               |           |      |        |        |       |
| Men               | 1        | 83   | 65     | 149    |       |
| Women             | 0        | 26   | 26     | 52     |       |
| Total             | 1        | 109  | 91     | 201    | 0.429 |
| Smoking           |           |      |        |        |       |
| Never             | 0        | 11   | 15     | 26     |       |
| Ex-smoker         | 0        | 24   | 25     | 49     |       |
| Regularly         | 1        | 53   | 42     | 96     |       |
| Total             | 1        | 88   | 82     | 171    | 0.158 |
| Heavy drinking    |           |      |        |        |       |
| No                | 0        | 29   | 32     | 61     |       |
| Previously        | 1        | 12   | 11     | 24     |       |
| Yes               | 0        | 28   | 10     | 38     |       |
| Total             | 1        | 69   | 53     | 123    | 0.016 |
| HPV               |           |      |        |        |       |
| Positive          | 1        | 45   | 54     | 100    |       |
| Negative          | 0        | 64   | 37     | 101    |       |
| Total             | 1        | 109  | 91     | 201    | 0.026 |
| Grade             |           |      |        |        |       |
| Gr1               | 0        | 9    | 9      | 18     |       |
| Gr2               | 0        | 42   | 36     | 78     |       |
| Gr3               | 1        | 58   | 46     | 105    |       |
| Total             | 1        | 109  | 91     | 201    | 0.595 |
| T class           |           |      |        |        |       |
| T1                | 0        | 21   | 16     | 37     |       |
| T2                | 1        | 45   | 30     | 76     |       |
| T3                | 0        | 20   | 26     | 46     |       |
| T4                | 0        | 23   | 19     | 42     |       |
| Total             | 1        | 109  | 91     | 201    | 0.414 |
| N class           |           |      |        |        |       |
| N0                | 0        | 20   | 19     | 39     |       |
| N+                | 1        | 89   | 72     | 162    |       |
| Total             | 1        | 109  | 91     | 201    | 0.603 |
| Stage             |           |      |        |        |       |
| I–II              | 0        | 14   | 16     | 30     |       |
| III–IV            | 1        | 95   | 75     | 171    |       |
| Total             | 1        | 109  | 91     | 201    | 0.336 |
| Tumor site        |           |      |        |        |       |
| Anterior wall     | 0        | 37   | 24     | 61     |       |
| Lateral wall      | 1        | 58   | 57     | 116    |       |
| Posterior wall    | 0        | 2    | 1      | 3      |       |
| Superior wall     | 0        | 12   | 9      | 21     |       |
| Total             | 1        | 109  | 91     | 201    | 0.747 |
| Cell-membranous β-catenin expression | | | | |
| Negative          | 0        | 7    | 4      | 11     |       |
| Weak              | 0        | 21   | 10     | 31     |       |
| Moderate          | 0        | 41   | 20     | 70     |       |
| Strong            | 1        | 40   | 48     | 89     |       |
| Total             | 1        | 109  | 91     | 201    | 0.026 |

Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma. Chi-square test was done with exact p-value.

Correlation Between Markers and Other Clinicopathological Parameters and Survival

Alcohol Use. Both the vimentin and cell-membranous expression of β-catenin appeared more frequently among patients with no history of heavy alcohol use (p=0.020 and p=0.016, respectively) (Tables 2 and 3).

Metastases. Moderate or strong expression was seen in 83% (135/163) of HPV-positive tumors and only in 62% (24/39) of HPV-negative tumors. The cell-membranous expression of β-catenin was positively associated with the presence of regional metastasis (p=0.036) (Table 3).

Tumor Grade. E-cadherin was significantly associated with tumor grade. It was expressed in all grade 1 tumor samples, but not in all grade 2 and 3 tumors. In addition, 50% of grade 1, 27% of grade 2, and 33% of grade 3 tumors exhibited a strong E-cadherin expression (p=0.020) (Table 1).

Other Clinicopathological Factors. We found no significant relationship between β-catenin (cell-membranous and cytoplasmic), E-cadherin, and vimentin expression in HPV-positive tumors. In addition, 54% (54/100) of HPV-positive tumors exhibited a strong vimentin expression, whereas only 37% (37/101) of HPV-negative tumors exhibited a strong vimentin expression. The stromal vimentin expression was stronger among HPV-positive tumors (p=0.026) (Table 2).
Table 3. Cell Membranous and Cytoplasmic Expression of β-Catenin and Their Associations With Clinicopathological Factors in OPSCC.

| Variables | Cell-Membranous β-Catenin Scoring | Cytoplasmic β-Catenin Scoring |
|-----------|----------------------------------|------------------------------|
|           | Negative | Weak | Moderate | Strong | Total | p Value | Negative | Weak | Moderate | Strong | Total | p Value |
| Sex       |          |      |          |        |       |         |          |      |          |        |       |         |
| Men       | 11       | 20   | 54       | 65     | 150   | 34      | 16      | 37     | 63      | 150   | 0.687* |          |
| Women     | 1        | 11   | 16       | 24     | 52    | 9       | 4       | 19     | 20      | 52    | 0.588* |          |
| Total     | 12       | 31   | 66       | 87     | 202   | 38      | 21      | 55     | 82      | 202   | 0.243* |          |
| Smoking   |          |      |          |        |       |         |          |      |          |        |       |         |
| Never     | 1        | 4    | 7        | 14     | 26    | 3       | 5       | 7      | 11      | 26    | 0.243* |          |
| Ex-smoker | 2        | 6    | 18       | 23     | 49    | 13      | 6       | 17     | 13      | 49    | 0.414* |          |
| Regularly | 7        | 15   | 34       | 40     | 96    | 18      | 6       | 24     | 48      | 96    | 0.243* |          |
| Total     | 10       | 25   | 55       | 75     | 171   | 34      | 17      | 48     | 72      | 171   | 0.307* |          |
| Heavy drinking | 8 | 14 | 45 | 56 | 123 | 3 | 14 | 56 | 83 | 202 | 0.020** |
| No        | 2        | 5    | 23       | 31     | 61    | 8       | 7       | 20     | 41      | 61    | 0.020** |
| Previously| 1        | 2    | 10       | 11     | 24    | 6       | 2       | 7      | 9       | 24    | 0.414* |          |
| Yes       | 5        | 7    | 12       | 14     | 38    | 6       | 3       | 9      | 20      | 38    | 0.414* |          |
| Total     | 8        | 14   | 45       | 56     | 123   | 20      | 12      | 36     | 55      | 123   | 0.810* |          |
| HPV       |          |      |          |        |       |         |          |      |          |        |       |         |
| Positive  | 3        | 14   | 26       | 58     | 101   | 20      | 13      | 27     | 41      | 101   | 0.001* |          |
| Negative  | 9        | 17   | 44       | 31     | 101   | 23      | 7       | 29     | 42      | 101   | 0.952* |          |
| Total     | 12       | 31   | 70       | 89     | 202   | 43      | 20      | 56     | 83      | 202   | 0.138* |          |
| Grade     |          |      |          |        |       |         |          |      |          |        |       |         |
| Gr1       | 1        | 1    | 5        | 11     | 18    | 3       | 1       | 5      | 9       | 18    | 0.387* |          |
| Gr2       | 6        | 17   | 30       | 25     | 78    | 13      | 8       | 24     | 33      | 78    | 0.414* |          |
| Gr3       | 5        | 13   | 35       | 53     | 106   | 27      | 11      | 27     | 41      | 106   | 0.414* |          |
| Total     | 12       | 31   | 70       | 89     | 202   | 43      | 20      | 56     | 83      | 202   | 0.138* |          |
| T class   |          |      |          |        |       |         |          |      |          |        |       |         |
| T1        | 2        | 6    | 13       | 17     | 38    | 11      | 1       | 11     | 15      | 38    | 0.674* |          |
| T2        | 2        | 16   | 25       | 33     | 76    | 11      | 10      | 20     | 35      | 76    | 0.357* |          |
| T3        | 3        | 3    | 20       | 20     | 46    | 6       | 5       | 15     | 20      | 46    | 0.357* |          |
| T4        | 5        | 6    | 12       | 19     | 42    | 15      | 4       | 10     | 13      | 42    | 0.357* |          |
| Total     | 12       | 31   | 70       | 89     | 202   | 43      | 20      | 56     | 83      | 202   | 0.224* |          |
| N class   |          |      |          |        |       |         |          |      |          |        |       |         |
| N0        | 2        | 13   | 11       | 13     | 39    | 5       | 7       | 14     | 13      | 39    | 0.036* |          |
| N+        | 10       | 18   | 59       | 76     | 163   | 38      | 13      | 42     | 70      | 163   | 0.946* |          |
| Total     | 12       | 31   | 70       | 89     | 202   | 43      | 20      | 56     | 83      | 202   | 0.946* |          |
| Stage     |          |      |          |        |       |         |          |      |          |        |       |         |
| I–II      | 2        | 9    | 8        | 11     | 30    | 41      | 14      | 46     | 71      | 172   | 0.357* |          |
| III–IV    | 10       | 22   | 62       | 78     | 172   | 43      | 20      | 56     | 83      | 202   | 0.357* |          |
| Total     | 12       | 31   | 70       | 89     | 202   | 43      | 20      | 56     | 83      | 202   | 0.224* |          |
| Tumor site|          |      |          |        |       |         |          |      |          |        |       |         |
| Anterior wall | 3 | 10   | 20 | 28 | 61 | 14 | 7 | 14 | 26 | 61 | 0.199** |
| Lateral wall | 8 | 15   | 39 | 55 | 117 | 27 | 11 | 34 | 45 | 117 | 0.199** |
| Posterior wall | 0 | 0    | 2 | 1   | 3  | 0  | 0 | 1  | 2  | 3  | 0.199** |
| Superior wall | 1 | 6    | 9  | 5 | 21 | 2 | 2 | 7 | 10 | 21 | 0.118** |
| Total     | 12       | 31   | 70       | 89     | 202   | 43      | 20      | 56     | 83      | 202   | 0.224* |          |

Abbreviations: HPV, human papillomavirus; OPSCC, oropharyngeal squamous cell carcinoma.

*Chi-square test with asymptotic p-value. **Chi-square test with exact p-value.

and gender, smoking, tumor class (T class), or tumor stage and patient age (Tables 1–4). Survival. We found no significant relationship between the examined markers and patient survival.
**Discussion**

In this study, the cell-membranous expression of β-catenin was stronger in HPV-positive tumors than in HPV-negative tumors. This result is in accordance with the result of a previous study showing that β-catenin may accelerate HPV-mediated cervical carcinogenesis through the Wnt/β-catenin pathway.21 Thus, β-catenin may play the same role in HPV-related OPSCC. In addition, we found that a strong vimentin expression was more frequently seen in HPV-positive tumors than in HPV-negative tumors. We detected β-catenin positivity in OPSCC cells, whereas vimentin expression was solely seen in OPSCC-related stromal tissue and not in tumor cells. Schäfer et al.37 have suggested that vimentin may act as a binding protein for HPV16 pseudovirion and modulate the internalization of HPV16 pseudovirion in cervix carcinoma cell lines; with the results being adverse compared with ours, both HPV-positive and HPV-negative tumor cells were negative for vimentin expression, and we found no relation between stromal vimentin expression and HPV status.

In our article, E-cadherin expression was associated with both cell-membranous and cytoplasmic β-catenin immunoexpression. Similarly, this association has been identified in previous studies on different types of cancers.36,38 In addition, we found an association between the high expression of β-catenin and the presence of regional lymph node metastasis, a relationship that has been earlier identified in breast cancer too.22 Furthermore, in OPSCC, the low E-cadherin expression was associated with an increased risk of distant metastasis.40 Another study on breast cancer showed that the normal expression pattern of all proteins composing cadherin–catenin complex was associated with the absence of metastasis, and the alteration in the expression of one of these proteins impairs the adhesion and antimetastatic functions of other proteins in the same complex, increasing the risk of metastases.41 In our study, we observed a relationship between the presence of regional lymph node metastasis and a high expression of β-catenin. Thus, the high expression of β-catenin may hinder the cell-to-cell adhesion function of E-cadherin, increasing the risk of invasion and metastases, although we found no significant relationship between E-cadherin expression and metastasis.

Heavy alcohol use appears to associate with the development of HPV-negative OPSCC, and even light drinking appears to increase the risk of developing OPSCC.42 A study on hepatocellular carcinoma showed that alcohol consumption invigorates the Wnt/β-catenin signaling pathway, stimulating hepatocyte proliferation and promoting carcinogenesis.43 In addition, a study by Christopher et al.44 found that alcohol stimulates the expression of vimentin in breast and colon cancer cells. Contrary to this finding, we found that β-catenin and vimentin expression more frequently appeared among patients with no history of heavy alcohol use. One explanation for this discrepancy may be that different cancers have different biology and activate distinct signaling pathways.

In oral cancer, low E-cadherin expression appears to associate with a poor prognosis.16 In addition, high-grade OPSCC has a high recurrence rate.45 In HPV-negative OPSCC, García-Pedrero et al.46 showed that

| Table 4. The Relationship Between Age and the Prognostic Markers Used in the Study (E-Cadherin, β-Catenin, and Vimentin) With ANOVA. |
|-------------------------------------------------------------------------------------------------|
| Sum of Squares | Difference of Freedom | Mean Square | F Ratio | p Value |
|----------------|------------------------|-------------|---------|---------|
| E-cadherin     |                        |             |         |         |
| Between groups | 72.849                 | 3           | 24.283  | 0.240   | 0.869   |
| Within groups  | 20,053.412             | 198         | 101.280 |         |         |
| Total          | 20,126.261             | 201         |         |         |         |
| Cell-membranous β-catenin |                |             |         |         |
| Between groups | 104.310                | 3           | 34.770  | 0.344   | 0.794   |
| Within groups  | 20,021.951             | 198         | 101.121 |         |         |
| Total          | 20,126.261             | 201         |         |         |         |
| Cytoplasmic β-catenin |                 |             |         |         |
| Between groups | 211.451                | 3           | 70.484  | 0.701   | 0.553   |
| Within groups  | 19,914.810             | 198         | 100.580 |         |         |
| Total          | 20,126.261             | 201         |         |         |         |
| Vimentin       |                        |             |         |         |
| Between groups | 289.437                | 2           | 144.719 | 1.450   | 0.237   |
| Within groups  | 19,757.510             | 198         | 99.785  |         |         |
| Total          | 20,046.947             | 200         |         |         |         |
low membranous β-catenin and E-cadherin expression was associated with a poorer overall survival. In our cohort, a low E-cadherin expression was associated with a high tumor grade, although we found no correlation with prognosis. Similar results were previously found in studies of oral, oropharyngeal, and penile cancers.14,16,47 Although we found no relationship between E-cadherin and patient survival, we can deduce that the patients with low E-cadherin expression typically exhibit high-grade tumors, which have a higher likelihood of recurrence, and this may impact the survival.

To conclude, β-catenin, E-cadherin, and vimentin appear to have different roles in the pathogenesis of OPSCC. In addition, β-catenin may serve as a marker for the occurrence of regional metastasis. Moreover, in HPV-positive OPSCC, HPV infection may exploit the β-catenin and vimentin pathways in the carcinogenesis process—the former in the cancer tissue itself, and the latter in the tumor stroma.

Ethical Approval
This study was conducted in the Department of Pathology and Otorhinolaryngology—Head and Neck Surgery, University of Helsinki and Helsinki University Hospital (HUS). A hospital study permission was granted and institutional review board approval was obtained from the Research Ethics Committee of HUS (Dnro179/13/03/02/2013). In addition, we obtained a license from Valvira to use OPSCC tissue samples in this study (Drno 1004/06.01.03.01/2012). All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and adhered to the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Competing Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: After the study, Dr. Lauri Jouhi has become an employee at Orion Pharma. The other authors declare that they have no potential conflict of interest.

Author Contributions
All authors made substantial contributions to the analysis and interpretation of the data and results, and to the manuscript revisions. Each author has contributed to this work as follows: study concepts (JH, AM, CH, HM, LL, TA), study design (JH, CH), data acquisition (JH, HM), quality control of data and algorithms (LL), data analysis and interpretation (HM, LJ), statistical analysis (LL), manuscript preparation (HM, CH, JH, AM, TA, LJ), and manuscript editing (HM, CH, JH, AM, TA, LJ). All authors approved the manuscript for publication.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Helsinki University Hospital Research Funds, the Sigrid Juselius Foundation, the Otorhinolaryngology Research Foundation, the Finnish Dental Association, Apollonia, and the Libyan Ministry of Higher Education and Scientific Research.

Literature Cited
1. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42.
2. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shippins M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–15.
3. Angadi PV, Patil PV, Angadi V, Mane D, Shekar S, Hallikerimath S, Kale AD, Kardesai S. Immunoexpression of epithelial mesenchymal transition proteins E-cadherin, β-catenin, and N-cadherin in oral squamous cell carcinoma. Int J Surg Pathol. 2016;24(8):696–703.
4. de Moraes FPP, Lourenço SV, Janez RFC, de Sousa EA, da Conceição Silva MM, Damascena AS, Kowalski LP, Soares FA, Coutinho-Camillo CM. Expression of stem cell markers in oral cavity and oropharynx squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;123(1):113–22.
5. Swanson MS, Kokot N, Sinha UK. The role of HPV in head and neck cancer stem cell formation and tumorigenesis. Cancers. 2016;8(2):24.
6. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE, Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264(5157):436–40.
7. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res. 2005;11(16):5694–9.
8. Saito Y, Yoshida M, Omura G, Kobayashi K, Fujimoto C, Ando M, Sakamoto T, Asakage T, Yamasoba T. Prognostic value of p16 expression irrespective of human papillomavirus status in patients with oropharyngeal carcinoma. Jpn J Clin Oncol. 2015;45(9):828–36.
9. Huber GF, Albinger-Hegyi A, Soltermann A, Roessle M, Graf N, Haerle SK, Holzmann D, Moch H, Hegyi I. Expression patterns of Bmi-1 and p16 significantly correlate with overall, disease-specific, and recurrence-free survival in oropharyngeal squamous cell carcinoma. Cancer. 2011;117(20):4659–70.
10. Takeichi M. Molecular basis for teratocarcinoma cell-cell adhesion. Dev Biol. 1986;2:373–88.
11. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci. 1999;24(2):73–6.
12. Adhikary A, Chakraborty S, Mazumdar M, Ghosh S, Mukherjee S, Mann A, Mohanty S, Nakka KK, Joshi S, De A, Chattopadhyay S, Sa G, Das T. Inhibition of epithelial to mesenchymal transition by E-cadherin...
up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells. J Biol Chem. 2014;289:25431–44.

13. Fadare O, Reddy H, Wang J, Hileto D, Schwartz PE, Zheng W. E-cadherin and β-catenin expression in early stage cervical carcinoma: a tissue microarray study of 147 cases. World J Surg Oncol. 2005;3(1):38.

14. da Cunha IW, Souza MJL, da Costa WH, Amâncio AM, Fonseca FP, de Cassio Zequi S, Lopes A, Guimarães GC, Soares F. Epithelial-mesenchymal transition (EMT) phenotype at invasion front of squamous cell carcinoma of the penis influences oncological outcomes. Urol Oncol. 2016;34(10):433.e19–26.

15. Araki K, Shimura T, Suzuki H, Tsutsumi S, Wada W, Yajima T, Kobayashi T, Kubo N, Kuwano H. E/N-cadherin switch mediates cancer progression via TGF-β-induced epithelial-to-mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.

16. Pannone G, Santoro A, Feola A, Bufo P, Papagarakis P, Lo Muzio L, Staibano S, Ionna F, Longo F, Franco R, Aquino G, Contaldo M, De Maria S, Serpico R, De Rosa A, Rubini C, Papagarakis S, Giovane A, Tombolini V, Giordano A, Caraglia M, Di Domenico M. The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage. Curr Cancer Drug Targets. 2014;14(2):115–27.

17. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J. 1989;8(6):1711–7.

18. McCrea F, Gumbiner B. Purification of a 92-kDa cytoplasmic protein tightly associated with the cell-cell adhesion molecule E-cadherin (uvomorulin). Characterization and extractability of the protein complex from the cell cytoskeleton. J Biol Chem. 1991;266(7):4514–20.

19. McCrea PD, Turck CW, Gumbiner B. A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin. Science. 1991;254(5036):1359–61.

20. Kraus C, Liehr T, Hölsken J, Behrens J, Birchmeier W, Grzeschik K-H, Ballhausen WG. Localization of the human β-catenin gene (CTNNB1) to 3p21: a region implicated in breast cancer by up-regulating the chemokine CCL5. Exp Cell Res. 2015;338(1):22–31.

21. Bulut G, Fallen S, Beauchamp EM, Drebng LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A. Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice. PLoS ONE. 2011;6(11):e27243.

22. Yasuhara R, Irié T, Suzuki K, Sawada T, Miwa N, Sasaki A, Tsunoda Y, Nakamura S, Mishima K. The β-catenin signaling pathway induces aggressive potential in breast cancer by up-regulating the chemokine CCL5. Exp Cell Res. 2015;338(1):22–31.

23. Moles MAG, Montoya JAG, Salvago MDM, Ávila IR, Campillo JJP, Bravo M. Implications of differential expression of β-catenin in oral carcinoma. Anticancer Res. 2016;36(4):1599–604.

24. Brown S, Levinson W, Spudich JA. Cytoskeletal elements of chick embryo fibroblasts revealed by detergent extraction. J Supramol Struct. 1976;5(2):119–30.

25. Franke WW, Grund C, Kuhn C, Jackson BW, Illmensee K. Formation of cytoskeletal elements during mouse embryogenesis. III. Primary mesenchymal cells and the first appearance of vimentin filaments. Differentiation. 1982;23(1):43–59.

26. Bershadsky AD, Tint IS, Svitkina TM. Association of intermediate filaments with vinculin-containing adhesion plaques of fibroblasts. Cell Motil Cytoskeleton. 1987;8(3):274–83.

27. Tsuruta D, Jones JC. The vimentin cytoskeleton regulates focal contact size and adhesion of endothelial cells subjected to shear stress. J Cell Sci. 2003;116(24):4977–84.

28. Nieminen M, Henttinnen T, Marnila-Ichihara F, Eriksson JE, Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol. 2006;8(2):156–62.

29. Yang X, Wang J, Liu C, Grizzle WE, Yu S, Zhang S, Barnes S, Koopman WJ, Mountz JD, Kimberly RP, Zhang HG. Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol. 2005;167(3):705–19.

30. Kidd ME, Shumaker DK, Ridge KM. The role of vimentin intermediate filaments in the progression of lung cancer. Am J Respir Cell Mol Biol. 2014;50(1):1–6.

31. Richardson AM, HAVEL L, Koyen AE, Konen JM, Shupe JA, Wiles W, Martin WD, Grossniklaus H, Sica GL, Gilbert-Ross M, Marcus AI. Vimentin is required for lung adenocarcinoma metastasis via heterotypic tumor cell-cancer-associated fibroblast interactions during collective invasion. Clin Cancer Res. 2018;24(20):420–32.

32. Jouhi L, Mohamed H, Mäkitie A, Remes SM, Haglund C, Atula T, Hagström J. Toll-like receptor 5 and 7 expression may impact prognosis of HPV-positive oropharyngeal squamous cell carcinoma patients. Cancer Immunol Immunother. 2017;66(12):1619–29.

33. Makinen LK, Hayry V, Atula T, Haglund C, Keski-Santti H, Leivo I, Makitie A, Passadour-Santos F, Bockelman C, Salo T, Sorsa T, Hagstrom J. Prognostic significance of matrix metalloproteinase-2, -8, -9, and -13 in oral tongue cancer. J Oral Pathol Med. 2012;41(5):394–9.

34. Saukkonen K, Hagström J, Mustonen H, Juuti A, Norling S, Kallio P, Alitalo K, Seppänen H, Haglund C. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma. BMC Cancer. 2016;16(16):472.

35. Jeschke U, Mylonas I, Kuhn C, Shabani N, Kunert-Keil C, Schindbeck C, Gerber B, Friese K. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res. 2007;27(4A):1969–74.

36. Rismanchi S, Yadegar O, Muhammadnejad S, Amanpour S, Taghzadeh-Jahed M, Muhammadnejad A. Expression of vimentin filaments in canine malignant mammary gland tumors: a simulation of clinicopathological features of human breast cancer. Biomed Rep. 2014;2(5):725–8.
internalization of human papillomavirus 16 pseudovirions. J Virol. 2017;91(16):e00307–17.
38. Zaid KW. Immunohistochemical assessment of E-cadherin and β-catenin in the histological differentiations of oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2014;15(20):8847–53.
39. Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M, Monden T, Ito F, Monden M. Beta-catenin expression in human cancers. Am J Pathol. 1996;148(1):39–46.
40. Lefevre M, Rousseau A, Rayon T, Dalstein V, Clavel C, Beby-Defaux A, Pretet JL, Soussan P, Polette M, Guily JLS, Birembaut P. Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. Br J Cancer. 2017;116(3):362–9.
41. Bukholm I, Nesland J, Kåresen R, Jacobsen U, Børresen-Dale AL. E-cadherin and α-, β-, and γ-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol. 1998;185(3):262–6.
42. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, Pelucchi C, Bellocco R, Negri E, Corrao G, Rehm J, Boffetta P, La Vecchia C. Light alcohol drinking and cancer: a meta-analysis. Ann Oncol. 2012;24(2):301–8.
43. Mercer K, Hennings L, Ronis M. Alcohol consumption, Wnt/β-catenin signaling, and hepatocarcinogenesis. Adv Exp Med Biol. 2015;815:185–95.
44. Forsyth CB, Tang Y, Shaikh M, Zhang L, Keshavarzian A. Alcohol stimulates activation of Snail, epidermal growth factor receptor signaling, and biomarkers of epithelial-mesenchymal transition in colon and breast cancer cells. Alcohol Clin Exp Res. 2010;34(1):19–31.
45. Wang B, Zhang S, Yue K, Wang XD. The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. Chin J Cancer. 2013;32(11):614–8.
46. Garcia-Pedrero JM, Garcia-Cabo P, Angeles Villaronga M, Hermida-Prado F, Granda-Diaz R, Allonca E, Rodrigo JP. Prognostic significance of E-cadherin and β-catenin expression in HPV-negative oropharyngeal squamous cell carcinomas. Head Neck. 2017;39(11):2293–300.
47. Akhtar K, Ar A, Siddiqui S, Sherwani R. Diagnostic and prognostic significance of E-cadherin and vimentin in oral cancer metastasis. Ann Pathol Lab Med. 2016;3(1):A8–13.